Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)
This is a pilot, double blind randomized study conducted in patients scheduled to undergo
bone marrow transplant at the Massachusetts General Hospital. The goal of this study is to
look at the usefulness of bright light therapy in the prevention of delirium in a population
at high risk for developing this condition.
Delirium can develop in up to half of the people that undergo bone marrow transplant.
Symptoms include changes in level of alertness, confusion, and temporary problems with
memory and attention. In severe cases, it can be accompanied by agitation, paranoia(overly
suspicious), and hallucinations(seeing or hearing things that are not really there).
Bright light uses no medication and is often used to treat seasonal affective depression and
multiple sleep disorders. The light boxes are portable and are placed in front of
individuals for about 30 minutes every day.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention
Incidence of delirium (Time to the development of delirium based on meeting criteria on the Delirium Rating Scale and/or Memorial Delirium Assessment Scale)
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS)
From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
Carlos Fernandez-Robles, MD
Massachusetts General Hospital
United States: Institutional Review Board
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|